menu search

ALT / Altimmune Appears To Have A Winner, But Will The Market Believe?

Altimmune Appears To Have A Winner, But Will The Market Believe?
On September 14, shares plummeted 27% on topline results from a Phase 1 study of pemvidutide. Reductions in liver fat appear to be substantially better than that of the two leading drug candidates for nonalcoholic steatohepatitis. Read More
Posted: Dec 2 2022, 10:19
Author Name: Seeking Alpha
Views: 103195

ALT News  

5 Hot Penny Stocks To Watch In The Stock Market Today

By PennyStocks
October 25, 2023

5 Hot Penny Stocks To Watch In The Stock Market Today

Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, unde more_horizontal

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023

By GlobeNewsWire
October 25, 2023

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n more_horizontal

Altimmune: A Year Of Disappointment

By Seeking Alpha
October 11, 2023

Altimmune: A Year Of Disappointment

Altimmune's stock has disappointed shareholders over the past year, with disappointing trial results triggering a significant drop in equity in March more_horizontal

Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch ASAP

By PennyStocks
September 15, 2023

Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch ASAP

Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greate more_horizontal

Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study

By Zacks Investment Research
September 13, 2023

Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line more_horizontal

Altimmune to Participate at Two Upcoming Investor Conferences

By GlobeNewsWire
August 30, 2023

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that m more_horizontal

Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

By GlobeNewsWire
August 3, 2023

Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that i more_horizontal

Factbox: Weight-loss drugs: the next gold rush

By Reuters
June 27, 2023

Factbox: Weight-loss drugs: the next gold rush

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% more_horizontal


Search within

Pages Search Results: